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ABSTRACT
Accurate identification of cancer biomarkers and classification of cancer type
and subtype from High Throughput Sequencing (HTS) data is a challenging problem
because it requires manual processing of raw HTS data from various sequencing
platforms, quality control, and normalization, which are both tedious and timeconsuming. Machine learning techniques for cancer class prediction and biomarker
discovery can hasten cancer detection and significantly improve prognosis. To date,
great research efforts have been taken for cancer biomarker identification and cancer
class prediction. However, currently available tools and pipelines lack flexibility in data
preprocessing, running multiple feature selection methods and learning algorithms,
therefore, developing a freely available and easy-to-use program is strongly
demanded by researchers. Here, we propose CancerDiscover, an integrative opensource software pipeline that allows users to automatically and efficiently process
large high-throughput raw datasets, normalize, and selects best performing features
from multiple feature selection algorithms. Additionally, the integrative pipeline lets
users apply different feature thresholds to identify cancer biomarkers and build
various training models to distinguish different types and subtypes of cancer. The
open-source software is available at https://github.com/HelikarLab/CancerDiscover
and is free for use under the GPL3 license.

evaluation reports that distinguish cancer from normal
samples, as well as different types and subtypes of cancer.
Remarkable efforts have been put to develop gene
expression analysis tools and databases for cancer highthroughput data [2–11]. Several machine learning tools
have been developed to study cancer classification [12–
16]. However, Classifusion [14], ESVM [15], Prophet
[16] are either not available, abandoned or not maintained.
The available platforms require processed raw data that
have been normalized to address various technical and
statistical challenges such as, gene expression value
differences within the datasets and sequencing platform
bias. Moreover, different analysis steps have to be
performed manually by various tools, often using different
software platforms. These long and manual processing

INTRODUCTION
Classification of a tissue sample as cancer or normal
and among different tissue subtypes facilitates cancer
treatment, and high-throughput techniques generate
massive amounts of cancer data. Machine learning (ML)
has the potential to improve such classification, and
the traditional motivation behind ML feature selection
algorithms is to find the optimal subset of features.
However, no single feature selection algorithm or
classification algorithm can provide the best set of features
and classifiers [1]. Therefore, there is a need to develop
a pipeline that lets users apply different feature selection
algorithms, feature thresholds, and various classification
algorithms to generate accurate prediction models and
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steps are not only time-consuming but also error-prone,
making high-quality, large-scale ML analyses difficult.
To this end, we have developed CancerDiscover,
an integrative software pipeline, which, given raw,
bulk high-throughput data from various platforms, can
perform quality checks, normalize the data, select the
most important features from multiple feature selection
algorithms, and build and evaluate different machine
learning models in a streamlined fashion. Unlike software
tools that require manual processing and are limited in
feature selection and classification algorithm options (e.g.,
GenePattern [13] and Chipster [12]), CancerDiscover is
a fully automated pipeline, while providing users with
full control over each analysis step. CancerDiscover is
complementary to the data repositories, data visualization,
and the software tools such as ONCOMINE [9], INDEED
[10] and cBioPortal [11] that support data visualization
and analysis of differential gene expression. Herein,
we describe the open-source software and demonstrate
its utility and flexibility through a case study. We also
demonstrated the utility of CancerDiscover pipeline
using 2,175 gene expression samples from nine tissue
types to identify tissue-specific biomarkers (gene sets)
whose expression is characteristic of each cancer class
and built single-tissue and multi-tissue models [17]. In
the end, we provided the benchmarking statistics using
CancerDiscover for datasets of varying sizes.

(2).

(3).

(4).

RESULTS AND DISCUSSION
Implementation
The purpose of CancerDiscover pipeline tool is
to allow users to efficiently and automatically process
large high-throughput datasets by transforming various
raw datasets and selecting best performing features
from multiple feature selection algorithms. The pipeline
lets users apply different feature thresholds and various
learning algorithms to generate multiple prediction models
that distinguish different types and subtypes of cancer.
CancerDiscover takes raw datasets, normalizes it,
generates WEKA [18]-native (Attribute-Relation File
Format: ARFF) input files. The pipeline is illustrated in
Figure 1. CancerDiscover consists of eight components:
normalization, preliminary feature vector generation,
preliminary data partitioning, feature selection, feature
vector generation, data partitioning, model training
and model testing. These components are organized
into three scripts (masterScript_1, masterScript_2, and
masterScript_3). In addition to Bash, the CancerDiscover
pipeline is also implemented in SLURM (Simple Linux
Utility for Resource Management) to make it available for
high-performance computing clusters.

(5).

(6).

(1). Normalization: Due to the inherent differences
among samples obtained from various studies,
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normalization and background corrections are
required to remove or subdue bias in raw data for
accurate models. Once raw high-throughput data is
obtained, normalization and background corrections
are performed to remove the technical variation
from noisy data and background noise from signal
intensities and generated the expression set matrix
(for example, gene expression intensity values, etc.).
Preliminary Feature Vector Generation: Next,
the expression set matrix is used to create the master
feature vector in the WEKA-native file format
(ARFF).
Preliminary Data Partitioning (Stratified):
Stratified data partitioning was used by splitting the
master feature vector into training and testing sets to
maintain an even distribution of class distribution.
These training sets are used to construct the models
after feature selection has been performed in the next
step. Later, the model’s accuracy will be assessed
with the testing set, which had not been exposed to
the model, giving an honest assessment of the model.
Users of CancerDiscover can specify the size of the
data partition of their choice in the pipeline.
Feature Selection (on training data set only): Our
pipeline offers the ability to select multiple feature
selection algorithms. Each of these algorithms
provides the list of ranked features that distinguish
different types and subtypes of cancer. Users can
choose different feature thresholds and can explore
the relationship between the number of features
considered by the classification algorithms and model
accuracy. For example, the feature sets generated
can be separated into different feature thresholds
(including the top 1%, 10%, 33%, 66%, 100% of the
total number of ranked features as well as the top 25,
50 and 100 ranked features). Users can also arbitrarily
choose these thresholds to identify the minimum
number of features needed to achieve accurate
classification models. For a list of available feature
selection methods, see Supplementary File 2.
Feature Vector Generation: Since the classification
models must be built based only on the ranked
features, new feature vectors are generated based on
the ranked feature sets.
Data Partitioning (Stratified): Once the new feature
vectors are generated, each feature vectors file will
undergo a second data partitioning. This partitioning
seed value (or integer that defines the exact sequence
of a pseudo-random number) is the same as the one
used in the preliminary data partitioning. As such,
each new feature vector will be split into the same
training and testing sets as in step 3. The master
training and testing feature vectors and the new
training and testing feature vectors differ only in
the number of features; the master feature vectors
contain all of the features, whereas the newly created
Oncotarget

feature vectors contain only the features that ranked
according to different thresholds (Dimensionality
Reduction).
(7). Model Training: CancerDiscover provides a diverse
set of machine learning classification algorithms and
allows the user to build models as they see fit. Each
new training dataset from the above step undergoes
machine learning model construction using stratified
k-fold cross-validation to identify the optimal model.
(8). Model Testing: The model performance was assessed
by testing its accuracy using the testing dataset that
was kept hidden from the model. The model can also
be used to predict the class labels for the samples
in the unknown dataset. In the case study below,
we illustrate the utility of the software to classify
normal vs. cancerous tissues and adenocarcinoma vs.
squamous carcinoma based on gene expression data.

machine and an advanced version that consists of SLURM
(Simple Linux Utility for Resource Management) scripts
that can be run on a high-performance computer (HPC).
SLURM is a computational architecture used to organize
user requests into a queue to utilize high-performance
computing resources. Due to the sheer size of the highthroughput data and complexity of data processing steps,
it is recommended to use CancerDiscover on a highperformance compute cluster. The command-line pipeline
is compatible with Linux OS and Mac OSX.

Case study
Two kinds of ML models were generated and tested
to illustrate the possible application of the pipeline. The
first model was developed to classify tissue samples
as either cancerous or normal, according to their gene
expression patterns. Sample distributions were as follows:
237 tumor tissue samples and 17 histologically normal
tissue samples split evenly into testing and training data
sets. The Quantile Normalization Method [19] was used
to normalize the data, and the background correction was
performed using the Robust Multichip Average (RMA)
[20] parameter method by modifying the configuration
file for the case study presented in the paper. Filtered
Attribute Evaluator combined with Ranker method was
the algorithm selected (using pipeline configuration
file) to perform feature selection on the training dataset.
This algorithm outputs a list of all data features ranked
according to their utility in distinguishing the different

Installation/operation
CancerDiscover software is available at https://
github.com/HelikarLab/CancerDiscover.
All
the
components of the pipeline are organized into three
scripts (namely masterScript_1, masterScript_2, and
masterScript_3), each of which is composed of several
scripts (PERL, AWK, SHELL, BASH, R, and SLURM).
The detailed installation/operation of the pipeline is
described in the Supplementary File 1. There are two
versions of the CancerDiscover pipeline: the beginner
version consists of bash scripts that can be run on the local

Figure 1: Schematic representation of the CancerDiscover pipeline. First, raw data are normalized, background correction is

performed, and the output is partitioned into training and testing sets. The test set is held in reserve for model testing while the training set
undergoes a feature selection method. Feature selection provides a list of ranked attributes that are subsequently used to rebuild the training
and testing sets. The training dataset is subsequently used to build machine learning models. Finally, the testing data set is used for model
testing.
www.impactjournals.com/oncotarget
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classes of samples; features ranked at the top of the list
are most useful in distinguishing cancer from normal
samples. The plates used for this case study contain
approximately 10,000 full-length genes corresponding
to 12,625 probes (features). The top (0.25%, 0.5%, 1%,
10%, 33%, 100%) ranked features, as well as additional
feature sets containing the top (3, 6, 12, 100, 500) features
were used for generating several models simultaneously.
Training and testing accuracies are reported in Figure 2A2D. We selected RF and SVM as the machine learning
classification algorithms for the case study.
We achieved a model training accuracy of 98.43%
for the RF classifier using the top 0.25% (31 attributes)
of features. Models constructed using the top 3% of
ranked features reported an accuracy of 96.06%, while
models using the entire list of features (100%) resulted
in the lowest accuracy of 93.70%. Training accuracies
for the SVM classifier were 99.21% for the models
that used the top 3 features. Accuracy declined with the
increasing number of features, with models that used the
top 12 ranked features reporting an accuracy of 98.43%.
SVM resulted in the lowest (though still relatively high)
accuracy of 97.64% using 100 features. As few as the top
31 features are sufficient to achieve a higher accuracy,
using random forest classifiers, whereas top 3 features
are sufficient to achieve a higher accuracy using support
vector machines.
The second set of models was also bi-class; however,
the models were developed to distinguish lung sub-types
(adenocarcinoma vs. squamous cell carcinoma), rather
than tumor vs. normal tissue. 211 lung adenocarcinoma
and squamous cell carcinoma samples were evenly split

into training and testing datasets. After feature selection,
the list of ranked features was used to generate models
based on different feature thresholds. Results from testing
accuracies can be seen in Figure 2B. With the entire list
of ranked features, the RF testing accuracy was 91.51%,
increasing in accuracy as the percentage or number of
ranked features decreased. The top 1% of ranked features
(126 attributes) resulted in a model testing accuracy of
93.40% while the top 0.25% (31 attributes) of ranked
features resulted in testing accuracies of 95.28%. A
similar trend was seen going from the top 500 features to
the top 3 features. On average, SVM testing accuracies
were more consistent and higher than those based on RF.
The model generated with top 3 features resulted in an
accuracy of 96.23% while using the top 6 features led
to the accuracy of 95.28%. Using 100 features resulted
in a testing accuracy of 97.17%. Using the top 0.25%
and 0.5% resulted in accuracies of 96.23% and 97.17%,
respectively, while using the top 1% and 10% features led
to an accuracy of 98.11%. Using the top 33% of ranked
features resulted in the highest testing accuracy of 99.06%.
Precision, Recall, and F1-Score for the models generated
using the top 3 features are reported in Table 1.
As shown in Table 1, we were able to achieve a
high degree of accuracy using a small fraction of topranked features (3 features). This case study illustrates
the pipeline’s flexibility, utility, and ease-of-use in the
generation of several models simultaneously from raw
high-throughput data. It also highlights the customization
allowed by CancerDiscover on the individual steps of a
typical high-throughput data analysis pipeline, including
the data preprocessing, normalization methods, data

Figure 2: Model accuracies for the classification of tumor vs. normal and adenocarcinoma vs. squamous cell carcinoma:
RF represents Random Forest classifier and SVM indicates Support Vector Machine classifier. (A) Training accuracy for
Tumor vs. Normal model, (B) Training accuracy for Adenocarcinoma vs. Squamous Cell Carcinoma model, (C) Testing accuracy for
Tumor vs. Normal model, (D) Testing accuracy for Adenocarcinoma vs. Squamous Cell Carcinoma model.
www.impactjournals.com/oncotarget
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Table 1: Accuracies of random forest models using top 3 features
Training model

Precision

Recall

F1-Score

Tumor vs. normal

98.3

98.3

98.3

Adeno vs. squamous

97.9

98.9

98.4

Table 2: Benchmarking results
Feature selection
methods

Models
generated

Normalization
(Elapsed Time)

Feature selection
(Elapsed Time)

Model train & test
(Elapsed Time)

Total

500

20

665

2:05:32

21:45:59

8:05:32

31:57:03

200

20

650

0:52:31

14:16:55

4:49:33

19:58:59

100

20

665

0:26:56

13:31:22

3:12:30

17:00:48

50

20

665

0:16:48

12:06:42

2:58:56

15:12:26

10

19

585

0:07:03

10:05:17

2:14:05

12:26:25

Samples

All the datasets contain 54,675 features, and 2 CPUs were used for the analysis.
Elapsed time refers to the amount of real-time spent processing that function.
partitions, feature selection algorithms, classification
algorithms, and the threshold or percentage of ranked
features for additional analysis.

20 of the 23 possible feature selection algorithms were
completed, and subsequently utilized to generate 665
classification models. The 200-sample dataset provided 20
of the 23 possible feature selection outputs and produced
650 classification models. Lastly, the 500-sample dataset
contained 20 out of the possible 23 feature selection
outputs and generated 665 classification models. As the
datasets grew, the time required for cancer classification
increased linearly (Table 2).

CancerDiscover benchmarking
Benchmarking was performed using 500 samples
from Acute Myeloid Leukemia (AML) data (See
Data Collection section for more details) to assess the
performance of the software by running all the feature
selection and classification algorithms. The following
sample quantities were used; 500, 200, 100, 50 and 10.
Each dataset was run through the pipeline performing 23
feature selection algorithms (See Supplementary File 2
for the list of FS methods) and classification algorithms
to determine the required computational resources
such as the total amount of elapsed time for each step
of the pipeline and the total amount of elapsed time.
These factors, mainly depend on the size of the dataset
being processed. Benchmarking was performed using
computational resources at the Holland Computing
Centre of the University of Nebraska-Lincoln which has
106 nodes, 4 CPU per nodes. Table 2 below shows the
benchmarking results.
For the smallest set containing only ten samples, 19
of the 23 possible feature selection algorithms completed
processing (4 feature selection algorithms could not be
completed due to the 10-fold cross-validation used). For
those 19 feature selection algorithms, 585 classification
models were generated (few of the ARFF files were empty
for the lower feature thresholds due to the small number of
samples). The 50-sample dataset completed 20 of the 23
possible feature selection algorithms, thereby generating
665 classification models. When using 100 samples,
www.impactjournals.com/oncotarget

Comparison of CancerDiscover with other
methods
We compared the performance of CancerDiscover
with that of the three existing methods, GenePattern [13],
Chipster [12] and the method described in Aliferis et al.
[21]. We used the same train and test datasets to compare
the performance of CancerDiscover with these methods.
Results of this analysis are summarized in Table 3,
Supplementary Table 1 (Supplementary File 3), and
discussed in detail below.
GenePattern [13] is a web-based platform that
allows users to upload data and perform statistical analysis
and class prediction. Due to the nature of the data used in
this study, only SVM classification suite was used to draw
comparisons between CancerDiscover and GenePattern.
Because GenePattern could not perform normalization
and background correction for the given datasets, we
used the data normalized by the CancerDiscover pipeline
(using RMA method) and provided the normalized data
to the SVM classification module of GenePattern. The
input data contained all probes as GenePattern did not
provide feature selection options. ML classification
models were generated using the training data with
2569
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Table 3: Comparisons of machine learning classification components
Tool Components

CancerDiscover

GenePattern

Chipster

Aliferis

Normalization

ü

-

ü

-

Background correction

ü

-

-

-

Partitioning

ü

-

-

-

Feature selection

ü

-

-

ü

Modeling

ü

ü

ü

ü

This table highlights the capabilities of tools for performing different functions necessary to generate ML models.
accuracies of 98.43% for the Tumor vs. Normal model,
and 99.06% for the Adenocarcinoma vs. Squamous Cell
Carcinoma model. These higher accuracies could also
be due to the normalization and background correction
performed by the CancerDiscover pipeline. Of all the
three compared software tools, GenePattern’s accuracies
are most similar to the ones produced by CancerDiscover
– 99.21% and 99.06%, respectively. All probes were
utilized in the model building since feature selection could
not be performed using GenePattern. On the other hand,
CancerDiscover was able to achieve similar accuracy by
using as few as three probes (See Supplementary Table
1 in Supplementary File 3). Finally, CancerDiscover
differs from the proprietary GenePattern by the fact that
CancerDiscover is open-source; as such, its methodologies
are transparent and reproducible, and the community can
further expand the software.
Chipster is developed based on a client-server
architecture. Data is imported at the client side, while
all processing is performed on the server side using
R programming. It requires that all data need to be
transferred between client and server for each analysis
step which can be very time-consuming if the datasets
are large [22]. Chipster was not able to successfully
perform a classification when we provided the dataset
containing all probes. As a result, feature selection was
performed artificially; that is, the datasets provided to
Chipster contained only those probes selected by our
CancerDiscover feature selection method; thus, datasets
provided included the top 3, 6, 12, 100, or 500 probes.
Raw data in the form of CEL files were normalized
(RMA normalization) by Chipster. The accuracy using top
3 probes for the Tumor vs. Normal model was 97.63%,
whereas, for the Adenocarcinoma vs. Squamous Cell
Carcinoma model was 98.82%, ranking 3rd for the accuracy
assessment (See Supplementary Table 1 in Supplementary
File 3). These accuracy assessments for the CancerDiscover
are better than the results provided by Chipster.
Data used in this paper were also analyzed
independently in Aliferis et al. [21], using two feature
selection algorithms: Recursive Feature Elimination
and Univariate Association Filtering. These algorithms
identified 6 and 100 features, respectively, as significant
www.impactjournals.com/oncotarget

for cancer vs. normal classification, and 12 and 500
features, respectively, for adenocarcinoma vs. squamous
cell carcinoma classification. Aliferis et al. reported
average accuracies across classification algorithms:
94.97% for cancer vs. normal model, and 96.83% for
the squamous carcinoma vs. adenocarcinoma model.
In comparison, CancerDiscover resulted in 99.21%
accuracy for cancer vs. normal model, and 99.06% for
the adenocarcinoma vs. squamous cell carcinoma model,
while using only three features. In the context of these
data, CancerDiscover was more accurate, while using less
information than that of Aliferis et al.
These results demonstrate that the CancerDiscover
method is complementary to some of the existing methods,
such as GenePattern, Chipster, and Aliferis et al. methods,
and that it is also suitable for accurate classification of
other types of cancer types and subtypes. Although the
classification accuracy of CancerDiscover was marginally
higher than that of the compared methods, the strengths of
CancerDiscover lie in its streamlined nature that enables
users to begin with raw data and proceed to build machine
learning models within a complete pipeline. Another
strength of CancerDiscover is that it is flexible, allowing
users to utilize various methodologies within the platform,
and further extend the software as a whole due to its opensource nature.
In conclusion, we have developed a comprehensive,
integrative, open-source, and freely available pipeline,
CancerDiscover, which enables researchers to automate
the processing and analysis of high-throughput data
with the objective of both identifying cancer biomarkers
and classifying cancer and normal tissue samples
(including cancer sub-types). Herein, we showcased the
pipeline’s flexibility, utility, and ease-of-use in generating
multiple prediction models simultaneously from raw
high-throughput data. CancerDiscover allows users to
customize each step of the pipeline, preprocessing raw
data, selecting normalization methods, data partitions,
feature selection algorithms, and classification algorithms
for additional analysis. The CancerDiscover pipeline was
able to identify an optimal number of top-ranked features
and accurately classify the sample data into its classes.
Benchmarking demonstrated the high performance of the
2570
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pipeline across datasets of varying sizes. Researchers can
now utilize CancerDiscover for diverse projects, including
biomarker identification, and tissue classification
without extensive technical knowledge while retaining
significant flexibility. Another great advantage to the
biomedical community is that unlike GenePattern and
Chipster, CancerDiscover is open-source and freely
available and written in a modular fashion which opens
an array of opportunities for users to tweak the software
themselves for their needs, adding more algorithms as
it becomes available. Next, we will make our efforts
to develop graphical user interface and web server for
CancerDiscover with additional functionalities such as
querying, searching and downloading datasets from the
public repositories and data visualization of the outputs.

[25] and robust multichip average (RMA) [20] were used
for normalization and background correction, respectively.

Machine learning algorithms and framework
Though the pipeline supports the diverse set of
machine learning classifiers, we used Support Vector
Machines (SVMs) and Random Forests to construct
the models for the case study. These machine-learning
methods were chosen because of their extensive and
successful applications to datasets from genomic
and proteomic domains [26, 27]. Some of the cancer
classification tasks were binary (two classes), and the
others were multiclass (more than two classes). Though
SVMs are designed for binary classification, they can
also be used for multiclass classification by a one-versusrest approach [28]. The one-versus-rest approach for
classification is known to be among the best-performing
methods for multi-category classification for microarray
gene expression data [29]. Models were also constructed
using Random Forests (RF), which can solve multicategory problems natively through a direct application
[30]. Waikato Environment for Knowledge Analysis
(WEKA 3-6-11) [18] is a machine learning software
environment that serves as a platform for clustering and
classification of high-throughput data.

MATERIALS AND METHODS
The presented integrative pipeline consists of
existing open-source software tools and utilizes publicly
available datasets and various performance metrics.

Data collection
For the case study, lung cancer (tumor vs.
normal and adenocarcinoma vs. squamous carcinoma)
microarray gene expression data were collected from
the Broad Institute Cancer Program Legacy Publication
Resources database [23]. 237 tumor tissue samples and
17 histologically normal tissue samples, and 211 lung
adenocarcinoma and squamous cell carcinoma samples
were used. The plate used was Human Genome U95A
oligonucleotide probe arrays, containing 12,625 probes.
Benchmarking was performed using 500 samples of Acute
Myeloid Leukemia (AML) and normal blood sample
expression data downloaded from NCBI (GSE6891,
GSE2677, GSE43346, GSE63270) [HG-U133_Plus_2]
Human Genome U133 Plus 2.0 Array, containing 54,675
probes.

Performance measure
Accuracy was defined as the overall ability of
models to predict testing data correctly. Reported
measures included the numbers of true positives (TP),
true negatives (TN), false positives (FP), and false
negatives (FN). A true-positive count is the number of
samples in a dataset which were correctly categorized
into classes. A false-positive count is the number of
samples in a dataset which were sorted into the wrong
category. A true negative count represents the number of
samples which were not classified into a class to which
they do not belong, and false negatives are samples which
are not classified into the class to which they do belong.
Accuracy, Sensitivity (or Recall), Specificity, Precision,
F1-Score are derived from the measures mentioned
above as follows: accuracy is the ratio of correctly
predicted samples to the total number of samples.
Sensitivity is the proportion of true positives that are
predicted as positives. Specificity is the proportion of
true negatives which are predicted as negatives, and
Precision is the ratio of true positives to the total number
of true negatives and true positives. Lastly, F1-score is
defined as the harmonic mean of Precision and Recall
and is calculated by first multiplying precision and recall
values, then dividing the resulting value by the total of
precision and recall, and finally, multiplying the result
by two. The Accuracy, Sensitivity, Specificity, Precision,
and F1-Score are given by:

Normalization and background correction
Normalization and preprocessing are essential
steps for the analysis of high-throughput data. The Affy
R module 1.54 [24] from Bioconductor package (https://
bioconductor.org/packages/release/bioc/html/affy.html)
was used to remove the technical variation from noisy data
and background noise from signal intensities. This step is
crucial for analyzing large amounts of data which have
been compiled from different experimental settings where,
individual data files are processed to remove sample bias
from the data, which could otherwise introduce a bias in
the model. Affy R package provides multiple methods for
normalization and background correction, which can be
utilized within CancerDiscover using programmatic flags.
For the case study given above, quantile normalization
www.impactjournals.com/oncotarget
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Accuracy =

Computing Center at the University of Nebraska-Lincoln
for providing high-performance computing clusters
for machine learning modeling and benchmarking the
pipeline.

TP + TN
TP + TN + FP + FN

Recall / Sensitivity =

TP
TP + FN
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Specificity =

TN
TN + FP
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